Is Egrifta (Tesamorelin) Legal in Maryland?

HealthRX.com

Egrifta is FDA-approved, and Maryland's text sets no specific rule

Print or save as PDF

Key numbers

  • 1.4 mgDaily dose on the Egrifta SV label, which comes in a 2 mg vialSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 1.28 mgDaily dose on the Egrifta WR label, which comes in an 11.6 mg vialSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 1 mgFDA-listed vial strength of Egrifta, which carries a prescription marketing statusSource: accessdata.fda.gov, as cited Nov 7, 2026

See the public record for Tesamorelin

  • FDA status / Approved prescription drug, first approved November 10, 2010, application BLA 022505 [1]
  • FDA-listed strengths / Egrifta 1 mg per vial and 2 mg per vial, both with a marketing status of prescription [1]
  • Approved use / Excess abdominal fat in HIV-infected adults with lipodystrophy [2]
  • Current labels / Egrifta SV (2 mg vial) and Egrifta WR (11.6 mg vial), both dated July 29, 2026 [2][4]
  • Compounding / Not on FDA's significant-safety-risk list and in no category of FDA's state-licensed pharmacy or outsourcing facility lists [5][6][7]
  • Sport / WADA prohibits tesamorelin at all times, in and out of competition [8][9]

Federal Status: What the FDA Approval Covers

Egrifta was first approved on November 10, 2010, under application BLA 022505, which began as a new drug application and was later deemed a biologic license application [1]. Drugs@FDA lists Egrifta at 1 mg per vial and 2 mg per vial, and gives a marketing status of prescription for both [1].

The approved use is narrow. The label covers reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. It adds that long-term cardiovascular safety has not been established [2]. Use in people without HIV lipodystrophy sits outside the label [2].

The two current labels are Egrifta SV, a 2 mg vial with a 1.4 mg daily dose, and Egrifta WR, an 11.6 mg vial with a 1.28 mg daily dose. Both are injected subcutaneously into the abdomen once daily, and the WR label says the two are not substitutable [2][4].

What the Maryland Statute Text Shows

The Maryland provision is the definitions section that opens title 5 of the Criminal Law article. It defines administer as introducing a substance into the system of a human or animal by injection, inhalation, ingestion, application to the skin or another method. It defines an authorized provider as a person licensed, registered or otherwise allowed to administer, distribute, dispense or conduct research on a controlled dangerous substance in the state [3]. Definitions alone do not show whether Maryland adds tesamorelin-specific scheduling, prescribing or dispensing requirements.

Compounded Tesamorelin and FDA's Lists

FDA has not placed tesamorelin on its list of bulk drug substances that may present significant safety risks when used in compounding, content dated April 22, 2026 [5]. It also appears in no category of FDA's list for state-licensed pharmacies and physicians, updated May 14, 2026, or of FDA's list for outsourcing facilities, updated March 21, 2025 [6][7]. FDA has therefore made no category-based statement about compounding it.

Tesamorelin is not one of the six peptides named in HHS's draft enforcement-discretion policy for compounding, filed October 28, 2026 as Federal Register document 2026-22192 [10][11]. Compounded drugs are not FDA-approved: FDA does not review their safety, effectiveness or quality before they are marketed [10]. Tesamorelin is already a component of an FDA-approved drug [1][2].

Questions worth asking

Choose the questions you want to keep

Is Egrifta Approved for Weight Loss?

No. The label says Egrifta is not indicated for weight loss management because it has a weight-neutral effect [2].

Athletes: WADA Prohibits It

WADA's Prohibited List names tesamorelin in S2.2.4 among growth hormone releasing factors, and prohibits it at all times, in and out of competition [8]. It appears on the 2026 List, in force since January 1, 2026, and remains on the 2027 List [8][9].

Check what you know

Think you have it? Try 3 quick questions and see what the article says.

1. What does the label say Egrifta is approved to treat?

Question 1 of 3

Score: 0 right, 0 of 3 answered

What is Egrifta's regulatory status?
It is an FDA-approved prescription drug, first approved November 10, 2010, under application BLA 022505 [1]. Its only approved use is reducing excess abdominal fat in HIV-infected adults with lipodystrophy [2].
Do I need a prescription for Egrifta?
Yes. Drugs@FDA lists the 1 mg and 2 mg per vial Egrifta products with a marketing status of prescription [1].
Does Maryland have its own tesamorelin rules?
The Maryland provision this page draws on is a definitions section for title 5 of the Criminal Law article. It sets no tesamorelin-specific requirement [3].
Does the FDA approval cover weight loss?
No. The label says Egrifta is not indicated for weight loss management because it has a weight-neutral effect [2].
Show all 11 referencesHide references
Evidence overview for Is Egrifta (Tesamorelin) Legal in Maryland?